IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Leukemia, Lymphocytic, Acute
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
253 Active assets in the Leukemia, Lymphocytic, Acute cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
THIOGUANINE ANHYDROUS St. Jude Children's Research Hospital | Phase 4 | BBB |
Equine Atg Instituto Nacional de Cancer, Brazil | Phase 3 | BBB |
MERCAPTOPURINE ANHYDROUS Dana-Farber Cancer Institute | Phase 4 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →